PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
20.29
-0.14 (-0.66%)
Dec 20, 2024, 4:00 PM EST - Market closed
PureTech Health Revenue
PureTech Health had revenue of $288.00K in the half year ending June 30, 2024, a decrease of -95.90%. This brings the company's revenue in the last twelve months to $468.00K, down -96.01% year-over-year. In the year 2023, PureTech Health had annual revenue of $3.33M, down -78.68%.
Revenue (ttm)
$468.00K
Revenue Growth
-96.01%
P/S Ratio
n/a
Revenue / Employee
$5,200
Employees
90
Market Cap
465.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 694.97M |
UroGen Pharma | 89.36M |
Theravance Biopharma | 63.19M |
Zevra Therapeutics | 24.49M |
Verve Therapeutics | 24.40M |
MeiraGTx Holdings | 13.93M |
ABIVAX Société Anonyme | 9.68M |
PRTC News
- 5 days ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire
- 10 days ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 - Business Wire
- 12 days ago - PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting - Business Wire
- 4 weeks ago - PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors - Business Wire
- 2 months ago - PureTech to Present at CHEST 2024 Annual Meeting - Business Wire
- 4 months ago - PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - PureTech Health plc – Half-Year Report - Business Wire
- 4 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire